Using Amphotericin B to Improve Airway Function in Cystic Fibrosis
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
This study is looking at how a drug called Amphotericin B can help improve lung function in people with cystic fibrosis by boosting the movement of important ions in their airways, potentially offering a new treatment option for those who don't respond to existing therapies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10892140 on NIH RePORTER |
What this research studies
This research investigates how Amphotericin B (AmB), a drug typically used to treat fungal infections, can restore the function of anion channels in the airways of patients with cystic fibrosis (CF). The study focuses on understanding how AmB can enhance the secretion of bicarbonate and chloride ions in airway cells, which is crucial for maintaining respiratory health. By examining the effects of AmB on CF airway epithelia, including those with mutations that do not respond to current therapies, the research aims to provide a new treatment option for individuals with CF. The approach includes both laboratory studies and potential clinical applications to assess the safety and effectiveness of AmB in improving lung function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis, particularly those with mutations that do not respond to existing CFTR modulators.
Not a fit: Patients without cystic fibrosis or those whose condition is unrelated to CFTR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment for cystic fibrosis that benefits patients with various CFTR mutations.
How similar studies have performed: Previous studies have shown promise in using Amphotericin B for similar applications, but this specific approach is still being explored and is not yet widely tested.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Welsh, Michael J. — University of Iowa
- Study coordinator: Welsh, Michael J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.